13 Ottobre 2026

Duvelisib

Study Shows Duvelisib Has Marked Response, Survival Benefit in Difficult-to-Treat Leukemia and Lymphoma Compared with Standard Therapy

Study Shows Duvelisib Has Marked Response, Survival Benefit in Difficult-to-Treat Leukemia and Lymphoma Compared with Standard Therapy

Redazione 7 Ottobre 2018
For some patients with difficult-to-treat leukemia and lymphoma, the investigational oral medicine duvelisib may significantly improve disease...
Per saperne di più Maggiori informazioni su Study Shows Duvelisib Has Marked Response, Survival Benefit in Difficult-to-Treat Leukemia and Lymphoma Compared with Standard Therapy